Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

ABSTRACT: Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

PROVIDER: PRJNA646225 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Search for SNPs associated with the pharmacogenomic profile of Benzidazole adverse reactions in Chagas Disease Homo sapiens patients.

2021-03-31 | GSE154421 | GEO

Expression data from skin of patients with adverse drug reactions (ADRs)

Project description:ADRs are immune mediated skin reactions of diverse severity and etiology. The patho-mechanisms are however not well understood. We used a gene expression array for the comparison of the gene expression profile of 2 cutaneous adverse drug reactions (MPR and AGEP) to normal skin.

2019-02-01 | GSE121421 | GEO

Expression data from skin of patients with adverse drug reactions (ADRs)

Project description:Expression data from skin of patients with adverse drug reactions (ADRs)

| PRJNA497293 | ENA

Affymetrix SNP array data for chicken samples

Project description:Affymetrix SNP array data for chicken samples

| PRJNA525994 | ENA

Affymetrix SNP array data for preeclampsia samples

Project description:Affymetrix SNP array data for preeclampsia samples

| PRJNA792399 | ENA

Affymetrix SNP array data for hepatocellular carcinoma tissue

Project description: Not available

| S-DIXA-D-1096 | biostudies-other

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer

Project description:Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the common treatment for colorectal, breast, neck and head cancers – either as monotherapy or in combination therapy. Adverse reactions (ADRs) to the treatment are common and often result in treatment discontinuation or dose reduction. Factors contributing to ADRs, including genetic variation, are poorly characterized. We performed exome array analysis to identify genetic variants that contribute to adverse reactions.Our final dataset consisted of 504 European ancestry individuals undergoing fluoropyrimidine-based therapy for gastrointestinal cancer. A subset of 254 of these were treated with Capecitabine. All individuals were genotyped on the Illumina HumanExome Array.

| EGAS00001002763 | EGA

Affymetrix SNP array data for paediatric ependymoma and constitutional DNA

Project description:Background: The high incidence of recurrence and unpredictable clinical outcome for paediatric ependymoma reflect the imprecision of current therapeutic staging and need for novel risk stratification markers. Gain of chromosome 1q has been reported as a frequent aberration and correlate of adverse outcome in ependymoma. We therefore evaluated a prognostic role for 1q25 gain across three age-defined European clinical trial cohorts of paediatric intracranial ependymoma. Methods: The frequency of 1q gain in paediatric ependymoma was assessed across 51 tumours (42 primary, 9 recurrent) using Affymetrix® 500K SNP arrays. Gain of 1q25 was evaluated by interphase FISH (iFISH) across 189 primary intracranial ependymomas from children treated on the CCLG/SIOP CNS9204 (n = 60) and BBSFOP (n = 65) adjuvant chemotherapy trials, or with primary post-operative radiotherapy (SIOP CNS9904/RT group, n = 64). Results were correlated with clinical, histological and survival data. Findings: Gain of 1q was the most frequent imbalance in primary (7/42, 17 %) and recurrent ependymomas (3/9, 33 %). Gain of 1q25 was the strongest independent predictor of tumour progression in both CNS9204 (HR 3·36, p = 0·0009) and BBSFOP (HR 4·10, p = 0·0009) trial cohorts. In contrast, 1q25 gain was not prognostic for the older CNS9904/RT only group (PFS: p = 0·37, OS: p = 0·95). Clinical variables implicated in adverse outcome amongst cohorts included incomplete tumour resection and posterior fossa location. Interpretation: This is the first study to prospectively identify then validate a prognostic genomic marker for childhood ependymoma across independent prospective trial groups. 1q25 gain predicts progression in primary chemotherapy cohorts but not those treated by post-operative radiotherapy. We propose 1q25 gain is incorporated as an adverse marker into future European chemotherapeutic clinical trial design.

2012-02-09 | GSE32101 | GEO

Affymetrix SNP array data for kidney transplant samples

Project description:Affymetrix SNP array data for kidney transplant samples

| PRJNA807291 | ENA

Affymetrix SNP array data for Cryptomeria japonica samples

Project description:Affymetrix SNP array data for Cryptomeria japonica samples

| PRJNA377702 | ENA